BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health ...

Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

This study analyzes BRCA testing patterns in U.S. breast cancer patients, highlighting barriers and disparities in access to genetic testing and precision care.

In the U.S., maternal mortality rates exceed most other developed countries, and a blood pressure pregnancy disorder called preeclampsia is one of the main contributors to this unfortunate statistic.

How do these factors combine to create a roadmap for companies navigating the direct access testing industry? On the third episode of our four-part series on direct access laboratory testing, Epstein ...

Sauce Labs Inc., a continuous testing solutions provider, today announced the general availability of its Real Device Access API, changing how the company delivers mobile testing infrastructure and ...

We've covered reimbursement considerations and physician ordering and specimen collection regulations. How does all of this come together to shape the future of the lab testing industry? We've covered ...

Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports Approximately 5%-10% of patients with ...